Skip to content

Zymeworks ZYME Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$65.32M+123%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's increase (decrease) in accounts receivable?
Zymeworks (ZYME) reported increase (decrease) in accounts receivable of $36K in Q1 2026.
How has Zymeworks's increase (decrease) in accounts receivable changed year-over-year?
Zymeworks's increase (decrease) in accounts receivable increased by 100.1% year-over-year, from -$31.22M to $36K.
What does increase (decrease) in accounts receivable mean?
Measures the net change in amounts owed to the company by customers for goods or services delivered on credit. An increase typically indicates rising sales or potential collection delays, while a decrease suggests effective cash collection or a slowdown in revenue generation.